Literature DB >> 21257105

Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.

Krishnaswami Vijayaraghavan1, Prakash Deedwania.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a significant role in pathophysiology of multiple disease states. RAAS blockade is beneficial in patients with hypertension, acute myocardial infarction, chronic heart failure, stroke, and diabetic renal disease. RAAS blockade with the combination angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) has demonstrated conflicting results in recent clinical trials. This article reviews the latest evidence of isolated ACEI or ARB use, their combination, and the role of aldosterone blockers and direct renin inhibitors in patients at risk, and makes recommendations for their use in the prevention of morbidity and mortality in cardiovascular disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21257105     DOI： 10.1016/j.ccl.2010.11.003

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN： 0733-8651            Impact factor:   2.213


  17 in total

1.  The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

2.  Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Mol Pharmacol       Date:  2015-06-29       Impact factor: 4.436

3.  Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus.

Authors:  Tadashi Yoshida; Laura Semprun-Prieto; Richard D Wainford; Sergiy Sukhanov; Daniel R Kapusta; Patrice Delafontaine
Journal:  Endocrinology       Date:  2012-01-10       Impact factor: 4.736

Review 4.  Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Pharmacol Res       Date:  2017-06-23       Impact factor: 7.658

Review 5.  Current therapeutic approaches to cardio-protection in hypertension.

Authors:  David Parra; Augustus Hough
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

6.  Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor.

Authors:  Xianming Zhang; Fulong Tan; Randal A Skidgel
Journal:  J Biol Chem       Date:  2013-10-09       Impact factor: 5.157

Review 7.  The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure.

Authors:  Quanbin Xu; Dane D Jensen; Hua Peng; Yumei Feng
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

Review 8.  Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.

Authors:  Maria M Patarroyo Aponte; Gary S Francis
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

9.  Aldosterone-induced microRNAs act as feedback regulators of mineralocorticoid receptor signaling in kidney epithelia.

Authors:  Nejla Ozbaki-Yagan; Xiaoning Liu; Andrew J Bodnar; Jacqueline Ho; Michael Bruce Butterworth
Journal:  FASEB J       Date:  2020-07-11       Impact factor: 5.191

10.  Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.

Authors:  Thomas D Giles; Thomas Alessi; Das Purkayastha; Dion Zappe
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.